Chinese biotech firms cash in on promising drug discoveries via licensing deals

Quick Summary:

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

The health sector gauge suffered losses ranging from 19 to 25 per cent in the last four years and underperformed the broader index in the past three years.

Licensing deals struck by Chinese biotech start-ups with overseas partners could potentially fetch billions in revenue if their drug candidates are successfully developed and launched, according to analysts.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Eric Ng

Category: Business

Markets: Hong KongChina

Topics: Msci Cure Drug Cent Trials Index Clinical Approval Marketing China Cancer

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-31 @ 17:00:08 (5 hours ago)

News Timezone: GMT +8:00

News Source URL: scmp.com

Language: English

Article Length: 163 words

Reading Time: 1 minutes read

Sentences: 5 lines

Sentence Length: 33 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © SCMP

News ID: 25665201

View Article Analysis

About SCMP

Main Topics: Business

Official Website: scmp.com

Update Frequency: 6 posts per day

Year Established: 1903

Headquarters: Hong Kong

News Last Updated: 1 hours ago

Coverage Areas: Hong Kong

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #42

Publisher Details

Frequently Asked Questions